麻豆女优

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 麻豆女优 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors’ Liability Premiums
  • Florida鈥檚 KidCare

TRENDING TOPICS:

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors' Liability Premiums
  • Florida鈥檚 KidCare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Nov 11 2016

Full Issue

Misconceptions About Methadone Undermine Opioid Treatment Efforts

Despite research that proves how effective methadone can be in treating addiction, there are still some who believe using it amounts to "trading one addiction for another."

Despite the nation鈥檚 decadelong surge in opioid addiction, large swaths of the U.S. still lack specialized opioid treatment centers that can dispense methadone, one of three medications available to treat addiction to heroin and prescription pain pills. The other two medications, buprenorphine (approved by the Food and Drug Administration in 2002) and Vivitrol (approved in 2010), can be prescribed by doctors. But for some patients, particularly those who have built up a high tolerance for opioids through prolonged use or high doses, methadone can be the only addiction medication that works. (Vestal, 11/10)

In other news on the opioid epidemic聽鈥

The Drug Enforcement Administration is poised to ban a little-known drug called U-47700, also known colloquially as 鈥減ink.鈥 The agency, which has the power to ban drugs for two or three years聽鈥渢o avoid an imminent hazard to the public safety,鈥 said Thursday the new regulation will take effect Monday. The DEA has cited聽46 deaths in the United States over the last two years in which U-47700 is a confirmed cause. That doesn鈥檛 include the widely reported deaths of two 13-year-olds in Utah, which were聽purportedly聽linked to the drug. (Boodman, 11/10)

In recent years, as drug overdoses have overtaken car accidents as the leading cause of accidental death in the U.S., sales of naloxone products have soared, from $21.3 million in 2011 to $81.9 million in 2015, according to QuintilesIMS. Within this market, Adapt Pharma鈥檚 Narcan nasal spray is the fastest-growing product. Part of its appeal is that, in theory, anybody can use it to save a life. You don鈥檛 need to be a doctor or have any medical training. (Gillette, 11/11)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 麻豆女优